President Donald Trump is set to announce a deal with drugmaker Regeneron on Thursday to lower the cost of its pharmaceutical products, as part of the White House's signature most-favored-nation drug pricing initiative. The agreement involves Regeneron reducing prices on current and future drugs for Medicaid and offering its cholesterol medication Praluent at $225 on the White House's discounted drug website TrumpRx, according to the deal first outlined by NOTUS and confirmed by White House press secretary Karoline Leavitt.
Background of the Initiative
This announcement comes as the Trump administration has been promoting efforts to provide economic relief ahead of November's midterm elections, with Americans citing high costs for health care, gas, groceries, and other essentials as straining their budgets. The deal is one of several most-favored-nation agreements the administration has struck with drug companies to align U.S. pharmaceutical prices with those in other developed nations. In July of last year, Trump publicly sent letters to executives at 17 major pharmaceutical companies regarding this issue. Regeneron is the final company among those to reach an agreement with his administration.
Details of the Agreement
As part of the deal, Regeneron has also committed to spending nearly $10 billion to bring pharmaceutical production to the United States, as reported by NOTUS. Historically, Trump's deals have offered companies relief on tariffs in exchange for such commitments. Despite the administration's touting of these drug-pricing deals as transformative, the specifics of the agreements have not been made public. When pressed by members of Congress to share the contracts this week, Health Secretary Robert F. Kennedy Jr. stated that his team would disclose whatever details it could that do not involve proprietary information or trade secrets. Trump and Kennedy have urged Congress to codify these deals into law.
Impact on Drug Prices
Drug prices for patients in the U.S. depend on various factors, including competition among treatments and insurance coverage. Most individuals have coverage through work, the individual insurance market, or government programs like Medicaid and Medicare, which protect them from much of the cost. Patients on Medicaid, a state and federally funded program for low-income individuals, already pay a nominal co-payment of a few dollars for prescriptions, but lower prices could benefit state budgets that fund these programs.
